Pricing Log in Create free account

Humacyte, Inc. (HUMA) vs Nkarta, Inc. (NKTX)

Humacyte, Inc. and Nkarta, Inc. are both Biotechnology companies. Humacyte, Inc. and Nkarta, Inc. are of similar size ($112.5M and $109.9M). Nkarta, Inc. has the higher net margin (0.00% vs −4,448.9%) and the higher return on invested capital (−127.2% vs −433.7%). Across the 14 metrics below, Nkarta, Inc. leads on 12 and Humacyte, Inc. on 2.

Valuation

Metric HUMA NKTX Biotechnology median
P/E n/m n/m 10.60
P/S 48.58 n/m 9.40
P/B 3.30 0.53 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.42 0.66
EV/Sales 41.40 n/m 9.02
Earnings yield (111.36%) (89.71%) (32.88%)
Free cash flow yield (94.68%) (72.03%) (23.13%)

Profitability

Metric HUMA NKTX Biotechnology median
Gross margin (494.58%) 0.00% 68.51%
Operating margin (5,240.78%) 0.00% 0.00%
Net margin (4,448.89%) 0.00% 0.00%
Free cash flow margin (4,599.72%) 0.00% 0.00%
Return on equity (534.42%) (38.76%) (51.96%)
Return on assets (68.16%) (29.86%) (46.06%)
Return on invested capital (433.66%) (127.22%) 0.00%

Growth

Metric HUMA NKTX Biotechnology median
Revenue growth (TTM) 149.82% — 6.76%
EPS growth (last fiscal year) 79.37% 11.88% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric HUMA NKTX Biotechnology median
Debt to equity 2.07 0.00 0.00
Current ratio 6.21 7.98 4.97
Net debt to EBITDA (0.12) 2.35 1.01

Dividend

Metric HUMA NKTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric HUMA NKTX Biotechnology median
Market cap 109.87m 112.45m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack